BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

69 related articles for article (PubMed ID: 35116576)

  • 1. Clonal Relationship and Mutation Analysis in Lymphoplasmacytic Lymphoma/Waldenström Macroglobulinemia Associated With Diffuse Large B-cell Lymphoma.
    Berendsen MR; van Bladel DAG; Hesius E; Berganza Irusquieta C; Rijntjes J; van Spriel AB; van der Spek E; Pruijt JFM; Kroeze LI; Hebeda KM; Croockewit S; Stevens WBC; van Krieken JHJM; Groenen PJTA; van den Brand M; Scheijen B
    Hemasphere; 2023 Nov; 7(11):e976. PubMed ID: 37928625
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Toripalimab plus lenalidomide for central nervous system recurrence in refractory CD5
    Chen X; Zhang Z; Zhang J; Yu Q; Qiu J; Xiao Y; Chen B; Xu P
    Transl Cancer Res; 2024 Feb; 13(2):1188-1195. PubMed ID: 38482415
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Influence of oncogenic mutations and tumor microenvironment alterations on extranodal invasion in diffuse large B-cell lymphoma.
    Shen R; Xu PP; Wang N; Yi HM; Dong L; Fu D; Huang JY; Huang HY; Janin A; Cheng S; Wang L; Zhao WL
    Clin Transl Med; 2020 Nov; 10(7):e221. PubMed ID: 33252851
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Zanubrutinib is effective in non-germinal-center B-cell-like diffuse large B-cell lymphoma with mutated
    Liu Y; Ma X; Wu X; Hou X; Jin W; Fu L; Xun X; Yu Y; Shen Z
    Leuk Lymphoma; 2024 May; ():1-11. PubMed ID: 38775302
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A promising natural product in diffuse large B-cell lymphoma therapy by targeting PIM1.
    Zhang X; Su Q; Zhang Y; Rong R; Chen S; He L; Zhuang W; Li B
    Ann Hematol; 2024 Mar; ():. PubMed ID: 38424303
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oncogenic Mutations of MYD88 and CD79B in Diffuse Large B-Cell Lymphoma and Implications for Clinical Practice.
    Visco C; Tanasi I; Quaglia FM; Ferrarini I; Fraenza C; Krampera M
    Cancers (Basel); 2020 Oct; 12(10):. PubMed ID: 33050534
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CD31 promotes diffuse large B-cell lymphoma metastasis by upregulating OPN through the AKT pathway and inhibiting CD8+ T cells through the mTOR pathway.
    He Z; Shen S; Yi Y; Ren L; Tao H; Wang F; Jia Y
    Am J Transl Res; 2023; 15(4):2656-2675. PubMed ID: 37193155
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Spatial Heterogeneity in Large Resected Diffuse Large B-Cell Lymphoma Bulks Analysed by Massively Parallel Sequencing of Multiple Synchronous Biopsies.
    Magnes T; Wagner S; Thorner AR; Neureiter D; Klieser E; Rinnerthaler G; Weiss L; Huemer F; Schlick K; Zaborsky N; Steiner M; Greil R; Egle A; Melchardt T
    Cancers (Basel); 2021 Feb; 13(4):. PubMed ID: 33561953
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Conformational transitions in BTG1 antiproliferative protein and their modulation by disease mutants.
    Kots E; Mlynarczyk C; Melnick A; Khelashvili G
    Biophys J; 2022 Oct; 121(19):3753-3764. PubMed ID: 35459639
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification and validation of 5-methylcytosine-associated genes in diffuse large B-cell lymphoma.
    Xing C; Zhu S; Yan W; Zhu H; Huang Z; Zhao Y; Guo W; Zhang H; Yin L; Ruan X; Deng Z; Wang P; Cheng Z; Wang Z; Peng H
    Heliyon; 2023 Nov; 9(11):e22209. PubMed ID: 38045198
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic value of baseline C-reactive protein in diffuse large B-cell lymphoma: a systematic review and meta-analysis.
    Huang Z; Wang K; Huang S; Lu Q
    Transl Cancer Res; 2023 Aug; 12(8):2169-2180. PubMed ID: 37701105
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genomic Profiling of Primary Diffuse Large B-Cell Lymphoma of the Central Nervous System Suggests Novel Potential Therapeutic Targets.
    Agostinelli C; Morandi L; Righi S; Cirillo L; Iommi M; Tonon C; Mazzatenta D; Zoli M; Rossi M; Bagnato G; Broccoli A; Lodi R; Zinzani PL; Sabattini E; Giannini C; Asioli S
    Mod Pathol; 2023 Dec; 36(12):100323. PubMed ID: 37678673
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prevalence And Clinical Significance Of Oncogenic
    Chen YP; Ke LF; Lu JP; Wang JC; Zhu WF; Chen FF; Lin SF; Xu CW; Wu MJ; Chen G
    Onco Targets Ther; 2019; 12():10165-10175. PubMed ID: 32063711
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MYD88, CARD11, and CD79B Oncogenic Mutations are Rare Events in the Indian Cohort of De Novo Nodal Diffuse Large B-Cell Lymphoma.
    Aggarwal V; Das A; Bal A; Srinivasan R; Das R; Prakash G; Malhotra P; Varma S
    Appl Immunohistochem Mol Morphol; 2019 Apr; 27(4):311-318. PubMed ID: 29734251
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular Pathogenesis of Diffuse Large B-Cell Lymphoma.
    Dobashi A
    J Clin Exp Hematop; 2016; 56(2):71-78. PubMed ID: 27980305
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Diffuse large B-cell lymphoma.
    Li S; Young KH; Medeiros LJ
    Pathology; 2018 Jan; 50(1):74-87. PubMed ID: 29167021
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of key mutations in central nervous diffuse large B-cell lymphoma (DLBCL) by comprehensive analysis between sequencing and TCGA database.
    Zhou C; Cui Y; Sun H; Yang F; Zhao H; Huangfu L; Zhang J
    Transl Cancer Res; 2021 Jun; 10(6):2632-2642. PubMed ID: 35116576
    [TBL] [Abstract][Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.